Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (generic name: lecanemab) has been approved for once every four weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback